Real-world Dosing Patterns of Rivaroxaban in the United States

Real-world Dosing Patterns of Rivaroxaban in the United States (RIVA-D)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03242278

Enrollment

12507

Registered

2017-08-08

Start date

2016-02-12

Completion date

2016-03-01

Last updated

2023-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Non-valvular atrial fibrillation (NVAF), Prevention, Stroke

Brief summary

The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban. The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).

Interventions

DRUGRivaroxaban (Xarelto, BAY59-7939)

As prescribed by treating physicians

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* NVAF (non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more inpatient or outpatient claims with International Classification of Disease ICD-9 427.31 as the diagnosis code at any time in the patient's data history prior to inclusion * Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics * CHA2DS2-Vasc score ≥2 during the 180 days prior to index rivaroxaban use baseline period * Evidence of continuous enrollment in MarketScan during 180 days before the date of the first prescription of rivaroxaban

Exclusion criteria

* Patients \<18 years of age * Patients with valvular AF (atrial fibrillation) * Pregnancy * Malignant cancers * Transient cause of AF * Patients with VTE (Venous thromboembolism), pulmonary embolism or DVT (Deep Vein Thrombosis) * Patients with major surgery defined as hip or knee replacement * Prescriptions of OACs (Oral anticoagulants) (apixaban,warfarin, dabigatran, rivaroxaban) before index date * Prescription of more than one OAC on the index date

Design outcomes

Primary

Measure	Time frame
Number of NVAF patients receiving 20 mg Rivaroxaban	At baseline
Number of NVAF patients receiving 15 mg Rivaroxaban	At baseline

Secondary

Measure	Time frame
Baseline renal function	At baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026